NEW YORK, June 29, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Lipocine, Inc. ("Lipocine" or the "Company") (NASDAQ: LPCN). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at email@example.com or 212-697-6484.
The investigation concerns whether Lipocine and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 29, 2016, pre-market, Lipocine revealed that the FDA issued a Complete Response Letter ("CRL") regarding its New Drug Application for LPCN 1021, an oral medication for testosterone replacement therapy in adult males with a deficiency or absence of endogenous testosterone, otherwise known as hypogonadism. The CRL listed insufficiencies regarding the algorithm for dosages and thus said the application was not ready for approval. Also, Lipocine's proposed titration scheme for clinical practice was very different from its Phase 3 trial titration scheme. This discrepancy in titration decisions between the Phase 3 trial and real-world clinical practice was also concerning. Following this news, Lipocine dropped as $3.67 per share or 58.61%, during intraday trading on June 29, 2016.
If you purchased Lipocine or if you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/#!lpcn/geg3g. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-lipocine-inc-lpcn-300292095.html
SOURCE Bronstein, Gewirtz & Grossman, LLC